BOSTON SCIENTIFIC CORP — Director's Dealing 2020

Feb 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2020-02-14

Reporting Person: Fitzgerald Joseph Michael (EVP & President, Rhythm Mgmt)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-07	Common Stock	G	695.0000	$0.0000	Disposed	208746.0000	Direct
2020-02-07	Common Stock	G	2085.0000	$0.0000	Disposed	206661.0000	Direct
2020-02-14	Common Stock	A	29723.0000	$0.0000	Acquired	236384.0000	Direct
2020-02-14	Common Stock	F	14669.0000	$42.3100	Disposed	221715.0000	Direct
2020-02-15	Common Stock	M	4614.0000	$0.0000	Acquired	226329.0000	Direct
2020-02-15	Common Stock	F	2278.0000	$42.3100	Disposed	224051.0000	Direct
2020-02-07	Common Stock	G	2085.0000	$0.0000	Acquired	6777.0000	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-15	Deferred Stock Units	$	M	4614.0000	Disposed	2023-02-15	Common Stock (4614.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	68400.0000	Indirect

Footnotes

F1: This transaction involved a gift of securities by the reporting person to his children, who share reporting person's household.

F2: On March 3, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

F3: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4: Balance reflects gifts made in 2018, 2019, and 2020 to certain of the reporting person's children that, as of the date of this report, share his household. The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose.

F5: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

F6: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.